<H1>Chapter DOI: 10.1007/978-1-60327-829-4_28<br/>Cited-By Count: 1</H1><table border="1" width="30%"><tr><td>Total References</td><td>24</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>24</td></tr><tr><td>BibStructured Count</td><td width="10%">23</td></tr><tr><td>BibUnstructured Count</td><td width="10%">1</td></tr><tr><td>DOI already available in SpringerLink</td><td>15</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>2</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>2</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>1</td></tr><tr><td>Valid DOI Enriched</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_28</td><td>BibArticle</td><td>Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2009;59:225&#8211;49.</td><td><a href=http://dx.doi.org/10.3322/canjclin.57.1.43>10.3322/canjclin.57.1.43</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_28</td><td>BibArticle</td><td>Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177:540&#8211;5.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2006.10.097>10.1016/j.juro.2006.10.097</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_28</td><td>BibArticle</td><td>Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R. Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004;10:8147&#8211;51.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-1402>10.1158/1078-0432.CCR-04-1402</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_28</td><td>BibArticle</td><td>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502&#8211;12.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa040720>10.1056/NEJMoa040720</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5_28</td><td>BibArticle</td><td>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513&#8211;20.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa041318>10.1056/NEJMoa041318</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_28</td><td>BibArticle</td><td>Berthold DR, Pond G, DeWit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study. ASCO Meeting Abstr 2007;25:50058.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1200/JCO.2007.12.4008>10.1200/JCO.2007.12.4008</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR7_28</td><td>BibArticle</td><td>Kirk TN, Moyad MA. National survey of advanced prostate cancer patients reveals disparity between perceptions and reality of treatment. J Clin Oncol (Meeting Abstracts) 2006;24:8590.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8_28</td><td>BibArticle</td><td>Drake, CG. Prostate cancer as a model for tumour immunotherapy. Nature Rev Immunol 2010;10:580&#8211;93.</td><td><a href=http://dx.doi.org/10.1016/S0921-4410(04)22011-7>10.1016/S0921-4410(04)22011-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_28</td><td>BibArticle</td><td>Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089&#8211;94.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.04.5252>10.1200/JCO.2005.04.5252</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_28</td><td>BibArticle</td><td>Haines AM, Larkin SE, Richardson AP, Stirling RW, Heyderman E. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 1989;60:887&#8211;92.</td><td><a href=http://dx.doi.org/10.1038/bjc.1989.385>10.1038/bjc.1989.385</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_28</td><td>BibArticle</td><td>Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002;117:471&#8211;7.</td><td><a href=http://dx.doi.org/10.1309/G6PR-Y774-X738-FG2K>10.1309/G6PR-Y774-X738-FG2K</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_28</td><td>BibArticle</td><td>Valone FH, Small E, MacKenzie M, et al. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J 2001;7 Suppl 2:S53&#8211;61.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13_28</td><td>BibArticle</td><td>Laus R, Yang D, Ruegg C. Dendritic cell immunotherapy of prostate cancer: preclinical models and early clinical experience. Cancer Res Ther Control 2001;11:1&#8211;10.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14_28</td><td>BibArticle</td><td>Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18:3894&#8211;903.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15_28</td><td>BibArticle</td><td>Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004;350:1461&#8211;3.</td><td><a href=http://dx.doi.org/10.1056/NEJMcibr045001>10.1056/NEJMcibr045001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_28</td><td>BibArticle</td><td>Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263&#8211;74.</td><td><a href=http://dx.doi.org/10.1038/nrc1586>10.1038/nrc1586</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_28</td><td>BibArticle</td><td>Takaue Y, Tanosaki R, Tobisu K, Kakizoe T, Mizunuma Y, Yanagida M, Kawai H. Antigen-pulsed dendritic cell therapy for the treatment of hormone-refractory prostate cancer: a phase I trial of APC8015. Proc ASCO 2002;21:1881.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18_28</td><td>BibArticle</td><td>Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6:2175&#8211;82.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19_28</td><td>BibArticle</td><td>Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004;60:197&#8211;204.</td><td><a href=http://dx.doi.org/10.1002/pros.20040>10.1002/pros.20040</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_28</td><td>BibArticle</td><td>Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005;4:55&#8211;60.</td><td><a href=http://dx.doi.org/10.3816/CGC.2005.n.013>10.3816/CGC.2005.n.013</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_28</td><td>BibArticle</td><td>Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006;107:67&#8211;74.</td><td><a href=http://dx.doi.org/10.1002/cncr.21956>10.1002/cncr.21956</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_28</td><td>BibArticle</td><td>Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670&#8211;9.</td><td><a href=http://dx.doi.org/10.1002/cncr.24429>10.1002/cncr.24429</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23_28</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Kantoff</span> <span style='background:#DDDDDD'>PW</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Higano</span> <span style='background:#DDDDDD'>CS</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Shore</span> <span style='background:#DDDDDD'>ND</span></span>, et al.</aug> <span style='background:#CCCCFF'>Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer</span>. <span style='background:#CCFF99'>N Engl J Med</span> <span style='background:#66FF66'>2010</span>;<span style='background:#FFCC66'>363</span>:<span style='background:#D279FF'>411&#8211;422</span>.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa1001294>10.1056/NEJMoa1001294</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Author_FamilyName_2, Author_FamilyName_1, VolumeID, Year, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR24_28</td><td>BibArticle</td><td>Beer TM, Bernstein GT, Corman JM, et al. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). J Clin Oncol (Meeting Abstracts) 2007;25:5059.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>